Clinical Trials Logo

Motor Neuron Disease clinical trials

View clinical trials related to Motor Neuron Disease.

Filter by:

NCT ID: NCT01160263 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls

DOSERAL
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the transporters of serotonin and dopamine in ALS patients in relation with the clinical phenotype, i.e., patients without stiffness, patients with pyramidal stiffness, patients with mixed (pyramidal and extra pyramidal) stiffness. For such a goal the investigators will use SPECT to compare the binding of two specific tracers in ALS patients and in matched healthy controls.

NCT ID: NCT01154283 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Study of Standard Noninvasive Positive Pressure Ventilation (NIPPV) and Low Expiratory Pressure NIPPV in ALS Patients

Start date: January 2008
Phase: N/A
Study type: Interventional

The purpose of the study is to test whether noninvasive positive pressure ventilation (NIPPV) without expiratory positive airway pressure (EPAP) (inspiratory positive airway pressure (IPAP)-only) will result in an increase in patient usage of NIPPV compared with standard NIPPV. Secondarily, the investigators will assess measures of dyspnea, quality of life, patient satisfaction, and side effects.

NCT ID: NCT01143428 Completed - Clinical trials for Motor Neuron Disease

Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study

Start date: May 13, 2010
Phase:
Study type: Observational

Background: - Primary lateral sclerosis (PLS) is a disorder in which nerve cells in the brain that control movement degenerate. The cause of PLS is not known, but some research has suggested that environmental factors that produce oxidative stress trigger PLS in people who carry certain genes. Oxidative stress is caused when the body makes chemicals called "free radicals" faster than its natural systems can break them down. Oxidative stress can be triggered by exposures to chemicals related to the bodily effects of lead, smoking, alcohol consumption, physical activity, and psychological stress. Chemicals produced by the body during oxidative stress can be measured in the blood and urine. Researchers are interested in studying the physical, neurological, and chemical effects of PLS to better understand the effects of oxidative stress on the disorder. Objectives: - To study the relation of oxidative stress to the diagnosis and progression of motor neuron disease. Eligibility: - Individuals 20 years of age or older who have been diagnosed with PLS, and have had symptoms of PLS for at least 5 but not more than 8 years and been previously enrolled in 01-N-0145 Screening: Neurologic Disorders with Muscle Stiffness Design: - Participants will have an initial study visit and three follow-up visits. Each visit will require approximately 3 days of testing at the National Institutes of Health Clinical Center. - As part of this study, participants will have the following tests and procedures: - Neurological examination to test muscle strength, sensation, coordination, and reflexes, as well as clarity of speech - Tests of memory, attention, concentration, and thinking - Surveys on oxidative stress, including questions on life, mood, jobs held, and habit - Electromyography to record the electrical activity of muscles - Transcranial magnetic stimulation to measure electrical activity translated from their brain to the muscles - Blood, urine, and skin biopsy samples for testing and sample collection - After the initial visit, participants will have three more visits, once each in the following 3 years.

NCT ID: NCT01142856 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Start date: June 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.

NCT ID: NCT01123200 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

An In-home Study of Brain Computer Interfaces

Start date: January 2010
Phase: N/A
Study type: Interventional

The investigators are developing a tool to help people who are severely paralyzed. This tool is called a brain-computer interface (BCI). BCIs can connect to computers or other electronic devices. This study allows a person with ALS to communicate, control their wheelchair tilt and perform other tasks using a BCI, thus increasing their independence.

NCT ID: NCT01119001 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A P300 Brain Computer Interface Keyboard to Control Assistive Technology For Use by People With Amyotrophic Lateral Sclerosis

Start date: February 2010
Phase: N/A
Study type: Interventional

People with Amyotrophic Lateral Sclerosis (ALS) will use a P300 based brain computer interface (BCI) keyboard to type in assistive technology devices. The results of this study will be compared with a previous study of a P300 BCI keyboard used by healthy volunteers.

NCT ID: NCT01091142 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Start date: July 2010
Phase: Phase 1
Study type: Interventional

Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS. Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS.

NCT ID: NCT01089010 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Start date: March 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357 on measures of skeletal muscle function or fatigability in patients with ALS.

NCT ID: NCT01083667 Completed - Clinical trials for Familial Amyotrophic Lateral Sclerosis

SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)

Start date: November 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study will be to evaluate the safety, tolerability and effect on SOD1 levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.

NCT ID: NCT01051882 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.

Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible treatment for patients with Amyotrophic Lateral Sclerosis (ALS) at the early and progressive disease stages.